Articles tagged with Cancer Immunotherapy
Researchers identified two novel biomarkers that predict response to immunotherapy and adverse events in liver cancer patients. The study's findings enable more effective and individualized treatment of primary liver cancer hepatocellular carcinoma (HCC) patients, with fewer side effects.
A clinical trial found that adding immunotherapy to standard treatment increased the likelihood of complete tumor eradication in patients with high PD-L1 expression. The combination could become a new standard of care if confirmed in larger trials.
A study by Osaka University found that fat accumulation in liver tumors can predict patient response to immunotherapy. The researchers identified a unique tumor immune microenvironment, known as steatotic HCC, which is associated with high infiltration of immune cells but exhaustion of nearby T cells.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
Researchers at University of Texas M.D. Anderson Cancer Center identify IL-6 as a key player in immunotherapy toxicity. A novel strategy combining IL-6 blockade with immune checkpoint blockade shows promise in reducing autoimmune side effects while preserving antitumor efficacy.
Researchers at Ochsner Health and MD Anderson have discovered that blocking interleukin-6 (IL-6) in lab models improves cancer responses while minimizing inflammation in healthy tissue. By targeting this cytokine, immune checkpoint inhibitors may become more targeted on tumors with fewer side effects.
Scientists discovered that intermittent dosing of PI3Kδ inhibitors can reduce toxicity while maintaining anti-tumor immunity in patients with head and neck cancers. This finding holds promise for improving treatment outcomes and saving lives.
The composition of microorganisms living in the gut influences response to conventional cancer treatments and novel immunotherapies. Recent studies suggest that targeting the gut microbiome could diminish side effects of chemotherapy, while diet, probiotics, and antibiotic medications may also impact clinical responses.
A team of researchers has discovered that cowpea mosaic virus, when injected into a tumor, triggers a powerful immune response, preventing cancer recurrence. The unique protein shell and RNA structure of the virus activate toll-like receptors, leading to increased cytokine production and a prolonged anti-cancer response.
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
Research reveals male sex hormones contribute to cancer-related sex bias via modulation of CD8+ T cells. Targeting this signaling cascade holds promise for improving cancer immunotherapies.
Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...
Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.
Researchers at Harvard Medical School have created spatial maps that show how melanoma cells and immune cells interact as a tumor develops. The maps, which offer insights into the early events in melanoma, reveal signs of immunosuppression and may aid in understanding how to prevent or treat the disease.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
Researchers found that combining durvalumab with novel agents like oleclumab and monalizumab increased major pathological response rates compared to solo durvalumab. The study also identified key immune cell signatures associated with treatment outcomes.
City of Hope researchers present new developments in cell therapy for acute myeloid leukemia and non-small cell lung cancer. A novel smoking cessation program increases patient desire to quit with personalized counseling.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Researchers at Tel Aviv University developed a drug delivery system based on lipid nanoparticles that utilize RNA to boost personalized cancer care. The nanodrug enhances chemotherapy effectiveness and reinvigorates the immune system, increasing sensitivity to cancer cells.
A new study found that omega-3 fatty acid supplementation can broadly improve immunotherapy and other anti-cancer drugs in the clinical setting. In mice, diets enriched with omega-3s blocked tumor growth when combined with immunotherapy or anti-inflammatory treatment, indicating possible synergistic anti-tumor activity.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Researchers at Ben-Gurion University have developed a potential treatment combination for advanced head and neck cancer, which shows promise in pre-clinical models. The therapy involves blocking a specific signaling pathway and sensitizing tumors to immunotherapy, resulting in the disappearance of tumors.
A new therapy combination of immunotherapy, chemotherapy and an anti-inflammatory drug may improve immune response in patients with muscle-invasive bladder cancer. The treatment activates cells to fight tumor growth, potentially leading to better outcomes for patients who don't respond to current treatments.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
In an animal study, researchers created an implantable biotechnology called MASTER that produces and releases CAR-T cells for attacking cancerous tumors. This technology reduces the manufacturing time from weeks to hours, increasing efficiency and effectiveness.
Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.
Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.
The Kwong Lab has developed a system of synthetic biosensors that can quickly assess the effectiveness of cancer treatment using non-invasive urinalysis. The sensors detect the presence of immune cells and tumor proteases, allowing for timely feedback on treatment response.
Researchers have identified a method to boost the effectiveness of CAR-T cell therapy by enhancing the metabolic activity of tumor-attacking T cells. The study's findings show that proline metabolism can be used to supercharge these cells, which may expand the treatment options for solid tumors.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
Researchers created implantable beads that produce high concentrations of interleukin-2, a natural compound activating white blood cells to fight cancer. The treatment eradicated ovarian and colorectal cancer in mice within six days, paving the way for human clinical trials later this year.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
A recent study published in Nature Medicine has confirmed the link between a healthy gut microbiome and the response to cancer immunotherapy. The study found that certain bacterial species, such as Bifidobacterium pseudocatenulatum, Roseburia spp., and Akkermansia muciniphila, are associated with a better immune response.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
A team of researchers has discovered blood biomarkers that can predict patient response to immunotherapy treatment for melanoma. The study found that patients with increased lactate levels and specific lipid and amino acid metabolites were more likely to respond to treatment.
Researchers develop a novel nanoplatform that can deliver drugs directly to T cells, which play a crucial role in immune reactions. The platform uses pH-sensitive dendrimers with phenylalanine and has shown promising results for cancer immunotherapy.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.
Researchers at the University of Helsinki discovered that tumour cells in ovarian cancer hide from the body's immune system by interacting with specific gene mutations. Tumours with BRCA1/2 mutations are more effectively targeted by killer T-cells, leading to better patient outcomes.
A recent study from Lund University found a previously unknown metabolic switch that regulates blood cell formation, enabling the directed production of natural killer cells for anti-cancer treatment. This discovery has significant implications for immunotherapy and cancer treatment.
A novel immune-profiling method can return detailed immune cell type proportions using only DNA from blood, potentially allowing for individualized prediction of outcomes in immunotherapy patients. This approach offers the opportunity to ask and answer questions about the immune system in health and disease.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers at Northwestern University have developed a novel microfluidic device that can efficiently harvest and sort tumor-eating immune cells from tumors. This technology has shown dramatic results in shrinking tumors in mice compared to traditional methods.
A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.
A retrospective analysis of 13 clinical trials found that most combination therapies involving immune checkpoint inhibitors worked due to independent drug action, rather than synergy or additivity. This discovery has implications for cancer clinical trial design and may help improve treatment outcomes.
A new study shows that treating mice with glioblastoma with interleukin-7 in combination with radiation improves survival rates. The therapy increases T cell numbers and activity against cancer cells, offering promise for patients with low lymphocyte counts.
Patients with skin-related side effects from immune checkpoint inhibitors tend to live longer, with a 22-50% decrease in mortality. These findings suggest that skin toxicities can be an indicator of treatment efficacy and may help identify patients who are more likely to benefit from their current immunotherapy regimen.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
Patients with sufficient fiber intake had improved progression-free survival and response to immunotherapy in melanoma. A high-fiber diet was associated with slower tumor growth and increased CD4+ T cells in pre-clinical models, supporting the potential benefits of dietary interventions on cancer treatment outcomes.
Researchers analyzed the largest cross-species database to assess species-specific cancer mortality rates and found conclusive proof that cancer risk is largely independent of body mass and life expectancy. The study highlights potent mechanisms of cancer resistance in larger species, contradicting intuitive expectations.
Scientists have identified the transcription factor Blimp1 as a new critical regulator of tumor-infiltrating regulatory T cells. Disrupting Blimp1 in these cells remodels the tumor microenvironment and augments the response to immunotherapy, promoting improved tumor control and anti-tumor immunity.
Researchers have discovered a nanoparticle therapeutic that enhances cancer immunotherapy and treats malignant pleural effusion. The treatment targets the immune system to recognize and eliminate cancer cells, improving survival rates and quality of life for patients.
Researchers developed nanoparticles that activate key cancer fighters by driving up immunity at the tumor site, improving interactions with antibody therapies. The technique left six of 10 mice with lymphoma tumor-free and was effective in melanoma when combined with existing immune response amplifiers.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
IN8bio is developing a genetically modified gamma-delta T cell technology to treat glioblastoma multiforme. Preclinical studies published in Scientific Reports show significant improvement in survival outcomes, and a Phase I clinical trial is underway at UAB.
Researchers at University of California San Diego found a way to boost innate immunity in liver cancer, making tumors highly responsive to immunotherapy. The combination of anti-PD-L1 antibody and polyIC molecule showed remarkable synergistic effects in liver tumor inhibition.